Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models.
Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, Kim RK, Bloomstein JD, Xiao Y, Bacal J, Saldivar JC, Le QT, Cimprich KA, Rankin EB, Giaccia AJ. J Clin Invest. 2021 Jun 1;131(11):146256. doi: 10.1172/JCI146256. PMID: 34060485 [PubMed]